A Novel Combination Therapy to Target Primitive Acute Myeloid Leukemia Cells

Modern molecular targeted therapies have shown promise in treating some blood cancers, but a cure remains elusive for most acute leukemia patients. This is largely due to the survival of some leukemic cells that possess unique properties and can cause treatment failure or relapse, warranting identification of new, distinct targets for improved therapies. In collaboration with Signalchem Lifescience Corporation (SLC), we aim to develop and test a new drug combination strategy to target acute myeloid leukemia (AML) patient cells that are resistant to current therapies. This pre-clinical study will evaluate the efficacy of novel inhibitors (developed by SLC), alone or in combination with available chemotherapeutics, to target primitive AML cells and their survival pathways in vitro and in vivo. We expect that this new combination will be more effective in eliminating critical leukemic patient cells compared to traditional single drugs, and provide directly proof-of-concept for a subsequent clinical trial.

Faculty Supervisor:

Xiaoyan Jiang

Student:

Katharina Rothe

Partner:

SignalChem Lifesciences Corporation

Discipline:

Genetics

Sector:

Medical devices

University:

Program: